SVRA Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of 27.14%. Savara, Inc.'s return on equity of -78.83% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 93.43%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 60.52%. Given that Savara, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Savara, Inc. is more attractive than ADMA Biologics, Inc..

Savara, Inc. has a beta of 0.336, which suggesting that the stock is 66.415% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Savara, Inc.'s net income of -$29.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 8.05x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of 16.99%. Savara, Inc.'s return on equity of -78.83% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 93.43%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.37%. Given that Savara, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Savara, Inc. has a beta of 0.336, which suggesting that the stock is 66.415% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Savara, Inc.'s net income of -$29.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 11.96x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -3.91%. Savara, Inc.'s return on equity of -78.83% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 93.43%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 43.73%. Given that Savara, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Savara, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

Savara, Inc. has a beta of 0.336, which suggesting that the stock is 66.415% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Savara, Inc.'s net income of -$29.6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 3.92x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Imunon, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of --. Savara, Inc.'s return on equity of -78.83% beat Imunon, Inc.'s return on equity of -365%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 93.43%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that Imunon, Inc. has higher upside potential than Savara, Inc., analysts believe Imunon, Inc. is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.336, which suggesting that the stock is 66.415% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Savara, Inc.'s net income of -$29.6M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.